Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Not Recruiting

Trial ID: NCT01254045

Age - 13 Years-29 Years Condition - Child Psychiatry Gender - Male Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Official Title

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Stanford Investigator(s)

Allan L. Reiss

Eligibility


Inclusion Criteria:

   1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).

   2. Male (who have more serious effects due to the X chromosome nature of the disorder)

   3. Age 13-29 years.

   4. Parent of adolescent must be willing to sign informed consent.

   5. Intelligence Quotient (IQ) > 42.

Exclusion Criteria:

   1. Cardiac risk factors.

   2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or
   atypical antipsychotics.

View More
View Less

Intervention(s):

drug: placebo

drug: oxytocin 24IU

drug: oxytocin 48IU

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Scott Hall
6504984799

©2024 Stanford Medicine